Gestational diabetes: opportunities for improving maternal and child health

Saravanan, Ponnusamy; Magee, Laura A.; Banerjee, Anita; Coleman, Matthew A.; Dadelszen, Peter von; Denison, Fiona C.; Farmer, Andrew; Finer, Sarah; Fox-Rushby, Julia; Holt, Richard; Lindsay, Robert; Mackillop, Lucy; Maresh, Michael; McAuliffe, Fionnuala M.; McCance, David R.; McCarthy, Fergus P.; Meek, Claire L; Murphy, Helen; Myers, Jenny; Pasupathy, Dharmintra; Poston, Lucilla; Reynolds, Rebecca M.; Scott, Eleanor M.; Sukumar, Nithya; Tan, Bee K.; Thangaratinam, Shakila; Webster, Louise; White, Sara L.; Williamson, Catherine

doi:10.1016/s2213-8587(20)30161-3

Cited by 255 publications

(206 citation statements)

References 74 publications

Supporting

Mentioning

172

Contrasting

Unclassified

Order By: Relevance

“…There is no time limit on when the GDM pregnancy occurred, so all women with a history of previous GDM are eligible but it is recommended that the HbA 1c be carried out within the past 12 months. This supports the widespread view that a major shift is needed in the clinical management of GDM; focusing not only on the short‐term obstetric and neonatal complications but also including increased emphasis on the longer‐term maternal risks of type 2 diabetes and cardiometabolic disorders 5 . This is highlighted by the recent distribution of coronavirus shielding letters to women with a history of previous GDM.…”

Section: Figuresupporting

confidence: 64%

2020 NICE guideline update: Good news for pregnant women with type 1 diabetes and past or current gestational diabetes

Murphy

2021

Diabet Med

View full text Add to dashboard Cite

Section: Figuresupporting

confidence: 64%

2020 NICE guideline update: Good news for pregnant women with type 1 diabetes and past or current gestational diabetes

Murphy

2021

Diabet Med

View full text Add to dashboard Cite

“…UCMSCs are attractive autologous or allogenic agents for the treatment of cancer and aging-related diseases (Ding et al, 2015). However, gestational diabetes is progressively prevalent and predicted to influence more than 20 million livebirths (about one in six) worldwide (Saravanan, 2020). Thus, considerably more work will need to be done to investigate the senescence of UCMSCs in the hyperglycemic environment.…”

Section: Discussionmentioning

confidence: 99%

Role of Hyperglycemia in the Senescence of Mesenchymal Stem Cells

Yin

Zhang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The regenerative and immunomodulatory properties of mesenchymal stem cells (MSCs) have laid a sound foundation for their clinical application in various diseases. However, the clinical efficiency of MSC treatments varies depending on certain cell characteristics. Among these, the roles of cell aging or senescence cannot be excluded. Despite their stemness, evidence of senescence in MSCs has recently gained attention. Many factors may contribute to the senescence of MSCs, including MSC origin (biological niche), donor conditions (age, obesity, diseases, or unknown factors), and culture conditions in vitro. With the rapidly increasing prevalence of diabetes mellitus (DM) and gestational diabetes mellitus (GDM), the effects of hyperglycemia on the senescence of MSCs should be evaluated to improve the application of autologous MSCs. This review aims to present the available data on the senescence of MSCs, its relationship with hyperglycemia, and the strategies to suppress the senescence of MSCs in a hyperglycemic environment.

show abstract

“…GDM is one of the most important endocrinopathies during pregnancy [1]. The label of GDM brings with itself an intervention package consisting of glucose monitoring; extra clinic visits; more obstetric monitoring with greater likelihood of intervention; a label of high risk for developing metabolic disturbances and diabetes in the mother [39].…”

Section: Discussionmentioning

confidence: 99%

“…Gestational diabetes mellitus (GDM) is considered a major pregnancy complication [1]. It has been defined as glucose intolerance in the second or third trimester of pregnancy in women who have had not clearly overt diabetes prior to gestation [2].…”

Section: Introductionmentioning

confidence: 99%

A Systematic Review of the Prevalence of Gestational Diabetes in Norway

Behboudi‐Gandevani

Parajuli

Vaismoradi

2021

IJERPH

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM) is a major public health problem and a threat to maternal and child health. There is a lack of integrated and systematically synthesized knowledge about the prevalence GDM in Norway. Therefore, this systemic review aimed to present the best available peer-reviewed published evidence from the past 20 years about the prevalence of GDM in Norway. A comprehensive literature search was performed on online databases consisting of PubMed (including Medline), Web of Science, and Scopus to retrieve original research articles published on the prevalence of GDM up to August 2020. Also, databases of Norart and SveMed+ in the Norwegian language were searched to enhance the search coverage. Data were extracted using a standardized protocol and data collection form and were presented narratively. A total of 11 studies were selected to include for data analysis and synthesis with the total sample size of 2,314,191 pregnant women. The studies included heterogenous populations and mostly reported the prevalence of GDM in healthy mothers with singleton pregnancies. The prevalence of GDM in population registered-based studies in Norway was reported to be lower than 2%, using the World Health Organization (WHO) 1999 criteria. However, studies on high-risk populations such as the non-European ethnicity reported prevalence rates ranging from 8% to 15%. Given the evidence from available literature that reported trends in the prevalence of GDM, an increase in the prevalence of GDM across most racial/ethnic groups studied in Norway was observed. Overall, the prevalence of GDM in the low risk population of Norway is fairly low, but the available literature supports the perspective that the prevalence of GDM has shown an increasing trend in recent decades. This finding is very important for health service planning and evaluation, policy development, and research in Norway. Large-scale prospective studies, using the national data, are warranted to provide firm evidence over coming years. Our review findings can help policy makers devise appropriate strategies for improving women’s reproductive health.

show abstract

Gestational diabetes: opportunities for improving maternal and child health

Cited by 255 publications

References 74 publications

2020 NICE guideline update: Good news for pregnant women with type 1 diabetes and past or current gestational diabetes

2020 NICE guideline update: Good news for pregnant women with type 1 diabetes and past or current gestational diabetes

Role of Hyperglycemia in the Senescence of Mesenchymal Stem Cells

A Systematic Review of the Prevalence of Gestational Diabetes in Norway

Contact Info

Product

Resources

About